LP352 ( DrugBank: - )

---

2 diseases

ID	Disease name (Link within this page)	Number of trials
140	Dorabe syndrome	2
144	Lennox-Gastaut syndrome	2

140. Dorabe syndrome

---

Clinical trials : 116 /  Drugs : 65 - (DrugBank : 17) / Drug target genes : 50 - Drug target pathways : 64

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05626634 (ClinicalTrials.gov)	November 8, 2022	15/11/2022	Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy	A Phase 2, Multicenter, Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy Who Completed Study LP352-201 and Are Candidates for Continuous Treatment for Up to 52 Weeks	Developmental and Epileptic Encephalopathy;Dravet Syndrome;Lennox-Gastaut Syndrome	Drug: LP352	Longboard Pharmaceuticals	NULL	Recruiting	12 Years	65 Years	All	50	Phase 2	United States
2	NCT05364021 (ClinicalTrials.gov)	March 3, 2022	22/3/2022	Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies	Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-escalation Study to Investigate the Safety, Tolerability, PK, PD, and Exploratory Efficacy of LP352 in Subjects With Developmental and Epileptic Encephalopathies	Developmental and Epileptic Encephalopathy;Dravet Syndrome;Lennox Gastaut Syndrome	Drug: LP352;Drug: Placebo	Longboard Pharmaceuticals	NULL	Recruiting	12 Years	65 Years	All	50	Phase 1/Phase 2	United States

144. Lennox-Gastaut syndrome

---

Clinical trials : 111 /  Drugs : 72 - (DrugBank : 14) / Drug target genes : 49 - Drug target pathways : 61

No.	TrialID	Date_ enrollment	Date_ registration	Public_title	Scientific_title	Condition	Intervention	Primary_ sponsor	Secondary_ sponsor	Recruitment_ Status	Inclusion_ agemin	Inclusion_ agemax	Inclusion_ gender	Target_ size	Phase	Countries
1	NCT05626634 (ClinicalTrials.gov)	November 8, 2022	15/11/2022	Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy	A Phase 2, Multicenter, Open-label, Long-term Safety Study of LP352 in Subjects With Developmental and Epileptic Encephalopathy Who Completed Study LP352-201 and Are Candidates for Continuous Treatment for Up to 52 Weeks	Developmental and Epileptic Encephalopathy;Dravet Syndrome;Lennox-Gastaut Syndrome	Drug: LP352	Longboard Pharmaceuticals	NULL	Recruiting	12 Years	65 Years	All	50	Phase 2	United States
2	NCT05364021 (ClinicalTrials.gov)	March 3, 2022	22/3/2022	Study to Investigate LP352 in Subjects With Developmental and Epileptic Encephalopathies	Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-escalation Study to Investigate the Safety, Tolerability, PK, PD, and Exploratory Efficacy of LP352 in Subjects With Developmental and Epileptic Encephalopathies	Developmental and Epileptic Encephalopathy;Dravet Syndrome;Lennox Gastaut Syndrome	Drug: LP352;Drug: Placebo	Longboard Pharmaceuticals	NULL	Recruiting	12 Years	65 Years	All	50	Phase 1/Phase 2	United States